New horizons in lung cancer management through ATR/CHK1 pathway modulation

被引：51

作者：

Thapa, Riya ^{[1
]}

Afzal, Obaid ^{[2
]}

Bhat, Asif Ahmad ^{[1
]}

Goyal, Ahsas ^{[3
]}

Alfawaz Altamimi, Abdulmalik Saleh ^{[2
]}

Almalki, Waleed Hassan ^{[4
]}

Alzarea, Sami, I ^{[5
]}

Kazmi, Imran ^{[6
]}

Singh, Sachin Kumar ^{[7
,8
]}

Dua, Kamal ^{[8
,9
]}

Thangavelu, Lakshmi ^{[10
]}

Gupta, Gaurav ^{[1
,11
]}

机构：

[1] Suresh Gyan Vihar Univ, Sch Pharm, Mahal Rd, Jaipur, India

[2] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Dept Pharmaceut Chem, Al Kharj 11942, Saudi Arabia

[3] GLA Univ, Inst Pharmaceut Res, Mathura, UP, India

[4] Umm Al Qura Univ, Coll Pharm, Dept Pharmacol, Mecca, Saudi Arabia

[5] Jouf Univ, Coll Pharm, Dept Pharmacol, Sakaka, Al Jouf, Saudi Arabia

[6] King Abdulaziz Univ, Fac Sci, Dept Biochem, Jeddah, Saudi Arabia

[7] Lovely Profess Univ, Sch Pharmaceut Sci, Phagwara 144411, India

[8] Univ Technol Sydney, Fac Hlth, Australian Res Ctr Complementary & Integrat Med, Ultimo, NSW 2007, Australia

[9] Univ Technol, Discipline Pharm, Grad Sch Hlth, Sydney, NSW 2007, Australia

[10] Saveetha Univ, Saveetha Inst Med & Tech Sci, Saveetha Dent Coll & Hosp, Dept Physiol,Ctr Global Hlth Res, Kuthambakkam, India

[11] Graphic Era Hill Univ, Sch Pharm, Dehra Dun 248007, India

来源：

FUTURE MEDICINAL CHEMISTRY | 2023年

关键词：

ATR; cancer; CHK1; DNA damage; lung cancer; NSCLC; SCLC; DNA-DAMAGE RESPONSE; ATR; INHIBITION; CHK1; AXIS; THERAPY; STRESS; REPAIR; CELLS; PP2A;

D O I：

10.4155/fmc-2023-0164

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Lung cancer is the leading cause of cancer-related deaths worldwide. Molecular profiling has contributed to a new classification of lung cancer, driving advancements in research and therapy. The ataxia telangiectasia and rad3/checkpoint kinase 1 (ATR/CHK1) pathway plays a crucial role in maintaining genomic stability, and its activation has been linked to the development of lung cancer, drug resistance and poor prognosis. Clinical and preclinical studies have demonstrated promising results in targeting this pathway. ATR and CHK1 are proteins that collaborate to repair DNA damage caused by radiation or chemotherapy. ATR/CHK1 inhibitors are currently under investigation in preclinical and clinical trials. This article explores the ATR/CHK1 pathway and its potential for treating lung cancer.

引用

页码：1807 / 1818

页数：12

共 50 条

[1] ATR/CHK1 inhibitors and cancer therapy
Qiu, Zhaojun
Oleinick, Nancy L.
Zhang, Junran
RADIOTHERAPY AND ONCOLOGY, 2018, 126 (03) : 450 - 464
[2] Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
Liu, Kang
Graves, Joshua D.
Lin, Fang-Tsyr
Lin, Weei-Chin
JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 296
[3] The suppression of ATR/Chk1 pathway by Elimusertib ATR inhibitor in triple negative breast cancer cells
Haciefendi, Ayten
Eskiler, Gamze Guney
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (07): : 4902 - 4911
[4] Lighting ATR/Chk1 by condensates
Qin, Yan
Shi, Lei
TRENDS IN CELL BIOLOGY, 2024, 34 (06) : 440 - 441
[5] Lutein inhibits tumor progression through the ATR/Chk1/p53 signaling pathway in non-small cell lung cancer
Zhang, Si-yu
Lu, You-yi
He, Xin-liang
Su, Yuan
Hu, Fen
Wei, Xiao-shan
Pan, Min-jie
Zhou, Qiong
Yang, Wei-bing
PHYTOTHERAPY RESEARCH, 2023, 37 (04) : 1260 - 1273
[6] Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy
Massey, Andrew J.
CANCER LETTERS, 2016, 383 (01) : 41 - 52
[7] Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugs
Toledo, Luis I.
Murga, Matilde
Fernandez-Capetillo, Oscar
MOLECULAR ONCOLOGY, 2011, 5 (04) : 368 - 373
[8] Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer (vol 297, 100924, 2021)
Liu, Kang
Graves, Joshua D.
Lin, Fang-Tsyr
Lin, Weei-Chin
JOURNAL OF BIOLOGICAL CHEMISTRY, 2021, 297 (01)
[9] ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells
Ronco, Cyril
Martin, Anthony R.
Demange, Luc
Benhida, Rachid
MEDCHEMCOMM, 2017, 8 (02) : 295 - 319
[10] PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway
Biegala, Lukasz
Gajek, Arkadiusz
Marczak, Agnieszka
Rogalska, Aneta
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1876 (02):

← 1 2 3 4 5 →